New Chemical Tools Let Scientists Probe a Little-Understood Alzheimer’s Protein

Scientists have built new chemical tools to study a poorly understood protein linked to Alzheimer’s disease — a step that could help uncover fresh targets for future treatments.

Researchers at Vanderbilt University’s Warren Center for Neuroscience Drug Discovery created two compounds aimed at the TAOK protein family, which has been tied to Alzheimer’s but was hard to investigate for lack of good research tools. Published August 3, 2026 in ACS Chemical Neuroscience.

What TAOK proteins do

TAOK proteins are kinases — enzymes that attach phosphate groups to other proteins, switching their activity on or off. Kinases are the principal mechanism by which cells route signals internally.

The Alzheimer’s connection runs through tau. TAOK kinases can phosphorylate tau, and excessive tau phosphorylation is central to the disease: it detaches tau from the microtubules it normally stabilises and drives aggregation into tangles.

Which kinases matter most in patients is unresolved. Several can phosphorylate tau in laboratory conditions, and establishing which do so consequentially in living brain tissue requires the ability to manipulate each one specifically.

Two opposite tools

One compound, VU6083859, is the first selective inhibitor of TAOK-1 — it turns the protein’s activity down. The other, VU6080195, does the opposite, activating all three members of the TAOK family.

Having tools that both block and boost lets scientists tease apart what the protein actually does.

The asymmetry between them is itself informative. The inhibitor is selective for one family member; the activator hits all three. Selectivity is generally easier to achieve with inhibitors, which bind a defined site, than with activators, which must engage a protein in a way that increases function — a subtler requirement.

Why an activator is unusual

“Our understanding of TAOK proteins largely centers around their inhibition, so we are excited at the prospect of studying the neurological effects of increasing their activity,” researcher Daniel Schultz said.

Most chemical biology is done with inhibitors, for a practical reason: blocking a protein is chemically straightforward, since occupying an active site prevents the enzyme working.

Making a protein work harder is harder to design. It generally requires binding elsewhere on the protein and inducing a shape change that improves catalytic function, and there is no general recipe for that.

The scientific cost of that imbalance is a systematic bias in what gets learned. Loss-of-function experiments answer what happens without a protein; gain-of-function experiments answer whether more of it is sufficient to produce an effect. Both are needed to establish a causal role, and the second has largely been unavailable here.

Tools, not medicines

These are research probes, not drugs — not suitable to give to patients.

The requirements genuinely differ. A tool compound needs potency and selectivity sufficient to produce interpretable results in a controlled experiment, and it must reach the cells being studied.

A drug additionally requires oral absorption or a practical route of administration, a duration of action allowing convenient dosing, freedom from toxicity across long exposure, no problematic interactions with other medicines, and manufacturability at scale.

Many excellent tool compounds fail every one of those tests, which is not a shortcoming — they were built for a different purpose.

Why the tools have to come first

Their value is in enabling the basic biology that has to precede drug development.

Without a selective compound, establishing what a kinase does in the brain relies on genetic approaches — deleting the gene, which removes the protein permanently and from development onward, so compensation obscures the result and effects on the adult brain cannot be isolated.

A chemical tool acts acutely and reversibly on a normally developed brain, which is a different and frequently more informative experiment.

Why kinases are hard to target selectively

The achievement of a selective TAOK-1 inhibitor is worth situating, because selectivity is the central difficulty in this protein class.

The human genome encodes over 500 kinases, and they share a common architecture: a binding pocket for ATP, the molecule supplying the phosphate they transfer. That pocket is structurally similar across the family, because it evolved to bind the same molecule.

Most kinase inhibitors work by occupying it, which means most bind numerous kinases to some degree. For cancer drugs that promiscuity is sometimes tolerable or even useful. For a research tool it is disqualifying — an effect observed after treatment cannot be attributed to one kinase if the compound hits twenty.

Achieving selectivity requires exploiting the small differences that do exist: variations in pocket size, in nearby residues, or in regions outside the ATP site that differ more between family members.

That is why publishing a selective probe is a contribution in its own right, and why the field maintains curated collections of validated tool compounds — a poorly characterised inhibitor generates results that are confidently wrong.

The activator in particular opens a direction few had been able to explore — the kind of groundwork that can eventually point toward new therapeutic strategies. Research news, not medical advice.